ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment
MOUNTAIN VIEW, Calif., June 24, 2020 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (NASDAQ: CCXI) today announced that it has identified an […]